<DOC>
	<DOC>NCT00568672</DOC>
	<brief_summary>Evaluation of olanzapine versus placebo in the continuation therapy of subjects with major depression who had a response with additional olanzapine to an antidepressant.</brief_summary>
	<brief_title>Optimal Duration of Olanzapine Add-on Therapy in Major Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>informed consent age 18 80 diagnosis of major depression according dsmiv, unipolar course HamiltonDepressionRatingScale (17 item score) &gt; 18 prior to inclusion response towards therapy with antidepressant and olanzapine as defined &gt; 50 % reduction of HAMDD score negative pregancy test highly effective contraceptive method in women no participation in other trial according to German Drug Laq normal liver function pregnancy, lactation depressive episode secondary to somatic disease or substance dependency contraindication for olanzapine treatment with interacting substances (CYP1A2 inhibitors or inductors) comorbidity according to DSMIV, axis I denail of consent hospital treatment by legal order hepatic insufficiency severe neurological or medical disease adipositas permagna HIVinfection active viral hapatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Major Depression</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>add-on therapy</keyword>
	<keyword>antidepressant</keyword>
	<keyword>atypical antipsychotic</keyword>
</DOC>